Literature DB >> 2009861

Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase.

B T Lin1, S Gruenwald, A O Morla, W H Lee, J Y Wang.   

Abstract

The retinoblastoma gene product (RB) is a nuclear protein which has been shown to function as a tumor suppressor. It is phosphorylated from S to M phase of the cell cycle and dephosphorylated in G1. This suggests that the function of RB is regulated by its phosphorylation in the cell cycle. Ten phosphotryptic peptides are found in human RB proteins. The pattern of RB phosphorylation does not change from S to M phases of the cell cycle. Hypophosphorylated RB prepared from insect cells infected with an RB-recombinant baculovirus is used as a substrate for in vitro phosphorylation reactions. Of several protein kinases tested, only cdc2 kinase phosphorylates RB efficiently and all 10 peptides can be phosphorylated by cdc2 in vitro. Removal of cdc2 from mitotic cell extracts by immunoprecipitation causes a concomitant depletion of RB kinase activity. These results indicate that cdc2 or a kinase with similar substrate specificity is involved in the cell cycle-dependent phosphorylation of the RB protein.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2009861      PMCID: PMC452726          DOI: 10.1002/j.1460-2075.1991.tb08018.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  47 in total

1.  Expression of recessive alleles by chromosomal mechanisms in retinoblastoma.

Authors:  W K Cavenee; T P Dryja; R A Phillips; W F Benedict; R Godbout; B L Gallie; A L Murphree; L C Strong; R L White
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

2.  Transforming gene product of Rous sarcoma virus phosphorylates tyrosine.

Authors:  T Hunter; B M Sefton
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

3.  Gene required in G1 for commitment to cell cycle and in G2 for control of mitosis in fission yeast.

Authors:  P Nurse; Y Bissett
Journal:  Nature       Date:  1981-08-06       Impact factor: 49.962

4.  Genetic control of the cell division cycle in the fission yeast Schizosaccharomyces pombe.

Authors:  P Nurse; P Thuriaux; K Nasmyth
Journal:  Mol Gen Genet       Date:  1976-07-23

5.  Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2.

Authors:  M G Lee; P Nurse
Journal:  Nature       Date:  1987 May 7-13       Impact factor: 49.962

6.  Production of large numbers of mitotic mammalian cells by use of the reversible microtubule inhibitor nocodazole. Nocodazole accumulated mitotic cells.

Authors:  G W Zieve; D Turnbull; J M Mullins; J R McIntosh
Journal:  Exp Cell Res       Date:  1980-04       Impact factor: 3.905

7.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

Review 8.  Genetics of retinoblastoma.

Authors:  F Vogel
Journal:  Hum Genet       Date:  1979-11-01       Impact factor: 4.132

9.  Human retinoblastoma susceptibility gene: cloning, identification, and sequence.

Authors:  W H Lee; R Bookstein; F Hong; L J Young; J Y Shew; E Y Lee
Journal:  Science       Date:  1987-03-13       Impact factor: 47.728

10.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma.

Authors:  S H Friend; R Bernards; S Rogelj; R A Weinberg; J M Rapaport; D M Albert; T P Dryja
Journal:  Nature       Date:  1986 Oct 16-22       Impact factor: 49.962

View more
  94 in total

1.  Cumulative effect of phosphorylation of pRB on regulation of E2F activity.

Authors:  V D Brown; R A Phillips; B L Gallie
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

2.  Immunohistochemical study of Cell Cycle Modulators in G(1)-S Transition in Clinical Breast Cancer Tissue.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

3.  Transforming growth factor beta 1 (TGF beta 1) reduces cellular levels of p34cdc2, and this effect is abrogated by adenovirus independently of the E1A-associated pRB binding activity.

Authors:  S E Abraham; M C Carter; E Moran
Journal:  Mol Biol Cell       Date:  1992-06       Impact factor: 4.138

4.  Transcriptional repression of the E2-containing promoters EIIaE, c-myc, and RB1 by the product of the RB1 gene.

Authors:  P A Hamel; R M Gill; R A Phillips; B L Gallie
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

5.  Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding.

Authors:  Y Qian; C Luckey; L Horton; M Esser; D J Templeton
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

6.  Molecular cloning of cellular genes encoding retinoblastoma-associated proteins: identification of a gene with properties of the transcription factor E2F.

Authors:  B Shan; X Zhu; P L Chen; T Durfee; Y Yang; D Sharp; W H Lee
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

Review 7.  Nuclear protein phosphorylation and growth control.

Authors:  D W Meek; A J Street
Journal:  Biochem J       Date:  1992-10-01       Impact factor: 3.857

Review 8.  Simian virus 40 large T antigen: the puzzle, the pieces, and the emerging picture.

Authors:  E Fanning
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression.

Authors:  J A DeCaprio; Y Furukawa; F Ajchenbaum; J D Griffin; D M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

10.  Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines.

Authors:  W Li; J Fan; D Hochhauser; D Banerjee; Z Zielinski; A Almasan; Y Yin; R Kelly; G M Wahl; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.